Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Trial sponsor
AMGEN
Scientific Title
A Randomized, Double-Blind Study Evaluating the Efficacy, Safety and Immunogenicity of ABP 798 Compared With Rituximab in Subjects With CD20 Positive B-Cell Non-Hodgkin Lymphoma (NHL)